Effect of Unani drug on thyroid disease

Efficacy of Jadwar in Subclinical Hypothyroidism: A Randomized Single Blind Placebo Controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042682

Enrollment

Registered

2022-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E02- Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention1: Jadwar in the form of capsule: 2gm/day for 56 days orally with water Control Intervention1: Placebo (starch) in the form of capsule: 2gm/day for 56 days orally with water

Eligibility

Inclusion criteria

Inclusion criteria: Patients between 20-60 years of age of either gender. Cases with TSH level between 5.5 and 15 mIU/L & Serum free thyroxine (fT4) level within normal range. Ability to provide written informed consent and understand the risks and benefits of the protocol.

Exclusion criteria

Exclusion criteria: Pregnancy and lactation. Complicated cases of Hypothyroidism, Diabetes, Liver Disorders, stroke, depression, or other neurologic/psychiatric disorders

Design outcomes

Primary

Measure	Time frame
Reduction in TSH levelTimepoint: 56 days	—

Secondary

Measure	Time frame
safety assessment like â?¢ AST, ALT â?¢ KFT (Blood Urea Serum Creatinine) Timepoint: 56 days	—

Countries

India

Contacts

Public ContactDr Mariyam Ahad

National Institute of Unani Medicine

dr.mariyamahad@gmail.com9412456250

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026